Overview Phase I Study of OPB-51602 in Patients With Hematologic Malignancies Status: Completed Trial end date: 2014-04-01 Target enrollment: Participant gender: Summary To determine the maximum tolerated dose (MTD) of OPB-51602 Phase: Phase 1 Details Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.